Turn Biotechnologies Signs Global Licensing Agreement with HanAll Biopharma to Develop Eye and Ear Therapies

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

TurnBio-HanAll-agree

More Like This

PR Newswire associated0

FDA Meeting Feedback Puts Turn Biotechnologies on Track to be First Longevity Company Taking Cell Rejuvenation Therapy to Clinic

PR Newswire associated0

Turn Biotechnologies' Expanded eTurna™ Delivery Platform Designed to Solve Delivery and Targeting Issues that Challenge Industry

PR Newswire associated0

Turn Biotechnologies First to Deliver mRNA into the Dermis Using Proprietary LNPs, With No Distribution to Other Organs

BioArctic and Eisai sign research evaluation agreement regarding BAN2802

ACCESSWIRE associated0

HanchorBio and Henlius Announce Strategic Collaboration to Develop Innovative Immunotherapies

PR Newswire associated0

GBI Biomanufacturing and Allterum Therapeutics Announce Strategic Collaboration to Manufacture Therapeutic Antibody for Clinical Trials

PR Newswire associated0

Signant Health Launches Signant Biotech to Accelerate and Streamline Clinical Development for Emerging Biopharmaceutical Organizations

PR Newswire associated0

Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology